Remote Ischaemic Preconditioning in Childhood Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-01

Study Completion Date

2022-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Survival rates of children with cancers have improved significantly in the recent few decades. Nonetheless, the side effect of this class of drugs on heart function remains to be an issue of concern. Exploration of new strategies to protect the heart in the long term is therefore of paramount importance in children undergoing treatment of cancers. Previous cardioprotective interventions hav focused on changing the formulation or rate of administration of anthracyclines but with no observable benefits. While dexrazoxane, an iron chelator, has shown to reduce cardiotoxic outcomes, there remains worries of an association between dexrazoxane use and an increased risk of developing secondary malignancies. Recently, the clinical application of remote ischaemic preconditioning (RIPC) as a non-invasive and an easily applicable non-pharmacological myocardial protective intervention has gained increasing interest. Remote ischaemic preconditioning is the phenomenon in which brief episodes of reversible ischaemia and reperfusion applied to one vascular bed render resistance to ischaemia reperfusion injury of tissues and organs distant away. It can be achieved by repeated 5-minute cycles of inflation and deflation of blood pressure cuff placed over the arm or leg to induce limb ischaemia and reperfusion injury. It is noteworthy that anthracycline cardiotoxicity and myocardial reperfusion injury occur through similar pathways. Hence, the investigators hypothesize that RIPC may reduce myocardial injury in children receiving anthracycline chemotherapy for childhood malignancies. The proposed study aims to conduct a parallel-group blinded randomized controlled trial study to investigate whether RIPC may reduce heart damage in childhood cancer patients undergoing anthracycline-based treatment, and to determine the effect of RIPC on the changes in levels of cardiac troponin T, and on the occurrence of clinical cardiovascular events and echocardiographic indices.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preventing Cardiac Sequelae in Pediatric Cancer Survivors

NCT01805778

Anthracycline-induced Cardiotoxicity

COMPLETED

Evaluation of Cardiac and Endothelial Function in Children and Adolescents Treated With Anthracycline

NCT07253077

Anthracycline Related Cardiotoxicity in Childhood Cancers Chemotherapeutic Toxicity Childhood Cancer Survivors

NOT_YET_RECRUITING

Epidemiology of Cardiotoxicity in Children With Cancer

NCT00005418

Cardiovascular Diseases Heart Diseases Heart Failure, Congestive +2 more

COMPLETED

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

NCT02717507

Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm

COMPLETED PHASE2

Radiation Therapy and the Natural History of Childhood Cancers

NCT00064883

Cancer Childhood Malignancy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Remote ischemic preconditioning (RIPC) protocol will be induced at baseline and before each dose of anthracycline cardiac surgery and once before induction of anesthesia by 3 cycles of 5-min upper or lower limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiotoxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention RIPC

The intervention RIPC protocol will be induced by three cycles of inflation of a blood pressure cuff placed over the upper or lower limb, where deemed to cause minimal discomfort to patient, to 15 mmHg above the systolic blood pressure for five minutes followed by five minutes of cuff deflation to 0 mmHg.

Group Type EXPERIMENTAL

Remote Ischaemic Preconditioning

Intervention Type PROCEDURE

The intervention RIPC protocol will be performed each time by three cycles of inflation of a blood pressure cuff placed over the arm or leg of your child, where deemed to cause minimal discomfort, to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.

Control

The control protocol involves only placement of blood pressure cuff but without inflation for 30 minutes.

Group Type PLACEBO_COMPARATOR

Control

Intervention Type OTHER

Placement of blood pressure cuff without inflation for 30 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remote Ischaemic Preconditioning

The intervention RIPC protocol will be performed each time by three cycles of inflation of a blood pressure cuff placed over the arm or leg of your child, where deemed to cause minimal discomfort, to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.

Intervention Type PROCEDURE

Control

Placement of blood pressure cuff without inflation for 30 minutes.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Remote Ischemic Conditioning Remote Ischaemic Conditioning Sham

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients aged 4 to 18 years old
* newly diagnosed patients with solid tumours or haematological malignancies referred for anthracycline-based chemotherapy
* no history of being treated with anthracycline-based regimens in the past.

Exclusion Criteria

* existence of congenital or acquired heart disease
* presence of syndromal disorders
* abnormal baseline echocardiographic assessment
* peripheral vascular disease that renders RIPC impossible
* a platelet count \<30,000/µL.

Minimum Eligible Age

4 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No